PhotoPoint review: Further results found in AMD drug trial Santa Barbara, CA-Miravant Medic

October 1, 2002

Santa Barbara, CA-Miravant Medical Technologies says 65.6% of patients who were treated three times over 2 years at a lower dose of its PhotoPoint SnET2 photodynamic therapy for wet age-related macular degeneration (AMD) maintained stable vision compared with 39.3% of patients taking placebo.